An appropriately named gene could be ... - Advanced Prostate...

Advanced Prostate Cancer

21,603 members27,047 posts

An appropriately named gene could be a new treatment target

SimonHL profile image
3 Replies

An Unexpected, & Novel, Target for Prostate Cancer – Our Biological Clock

news-medical.net/news/20210...

The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair

nature.com/articles/s41467-...

Written by
SimonHL profile image
SimonHL
To view profiles and participate in discussions please or .
Read more about...
3 Replies
TheTopBanana profile image
TheTopBanana

Thank you for posting this. Its so interesting if this means treatment should be given a specific time of the day. I understod that CRY-1 should be targeted and inhibited? I wonder what that does to the sleep cycles?

Spyder54 profile image
Spyder54

Thanks Simon,I agree. I am certain that healthy sleep patterns are one more important pieces of the puzzle (as I type here on my bedside iPad at 5:30am-at least went to sleep at 10pm).

We want DNA Damage to PCa cells, not DNA Repair of PCa cells. I have the ATM gene which also negatively repairs the DNA of PCa cells.

This Cry-1 is one more overlooked piece of the puzzle which will lead us to better outcomes. Will focus on healthy bedtime rituals/habits!

Mike

TheTopBanana profile image
TheTopBanana in reply to Spyder54

Do you understand the meaning of targeting CRY-1? What would that do to ones cycles?

Not what you're looking for?

You may also like...

New machine learning model could enable targeted gene therapies for genetic diseases

genetic diseases like cancer and diabetes. The model can predict which enhancers play a role in...

Promising new treatment for CRPC

could provide treatment for prostate cancer:...

Doctors suggest new names for low-grade prostate cancer.

for low-grade prostate cancer....

New prostate cancer treatment concept

castration-resistant prostate cancer....

New drug could revolutionise prostate cancer treatment

promising:...